8-KLeadership ChangesExhibits & Filings

LAM RESEARCH CORP 8-K Report, Executive Changes (Dec 28, 2020)

Filed December 28, 2020For Securities:LRCX

Summary

Lam Research Corporation (LRCX) filed an 8-K on December 28, 2020, to announce the adoption of a new Executive Severance Policy and an Executive Change in Control Policy, effective January 1, 2021. These new policies will supersede existing employment and change-in-control agreements for senior executives, which are set to expire at the end of 2020. The primary purpose of this filing is to outline the updated compensation and benefits provided to key executives under specific termination scenarios, including involuntary termination, termination related to an acquisition, disability, or death. Investors should note that these policies define the severance packages, including cash payments, medical benefits, and accelerated vesting of equity awards (stock options and RSUs), for "Covered Executives" and specific "Tier 1 Executives" (CEO, President, EVP). The details vary based on the nature of the termination and whether a change in control or acquisition is involved, with higher multiples of salary and incentive compensation provided in change-in-control or acquisition-related scenarios. The policies also include provisions for confidentiality, non-compete, and non-solicitation obligations, and are subject to compensation recovery policies.

Key Highlights

  • 1Lam Research adopted new Executive Severance and Change in Control Policies, effective January 1, 2021, replacing existing agreements.
  • 2These policies apply to "Covered Executives" (CEO, President, EVP, SVP) and "Tier 1 Executives" (CEO, President, EVP).
  • 3Severance benefits include cash payments (multiples of base salary and short-term incentive compensation), medical benefits, and accelerated vesting of equity awards (options, RSUs, mPRSUs/PRSUs).
  • 4Benefits are tiered based on termination type: involuntary termination (not related to change of control/acquisition), termination following an acquisition, disability, or death.
  • 5Significantly enhanced benefits are provided for terminations occurring in connection with a Change in Control or Acquisition, with higher multiples of salary and incentive pay.
  • 6The policies require executives to adhere to confidentiality, non-compete, and non-solicitation obligations to receive severance.
  • 7The new policies are designed to ensure executive retention and provide compensation security under various termination events, particularly those involving corporate transactions.

Frequently Asked Questions

The main purpose of this 8-K filing is to inform investors about Lam Research's adoption of new Executive Severance and Executive Change in Control Policies, which will take effect on January 1, 2021. These new policies replace expiring employment and change-in-control agreements for senior executives and detail the compensation and benefits they will receive upon termination under various circumstances.

The new policies standardize severance and change-in-control benefits for a defined group of senior executives, replacing individual employment and change-in-control agreements. They specify cash payments based on salary and short-term incentives, continued medical benefits, and accelerated vesting of equity awards, with terms varying based on the reason for termination and the presence of a change in control or acquisition.

Under the new policies, executives may receive a lump-sum cash payment (a multiple of base salary and average short-term incentive compensation), continued medical benefits, and accelerated vesting of unvested stock options, Restricted Stock Units (RSUs), and performance-based RSUs (mPRSUs/PRSUs). The exact amounts and vesting acceleration depend on the specific termination scenario (e.g., involuntary termination, termination due to change of control, disability, or death).

Yes, executives must fulfill certain conditions to receive the severance benefits. These include performing their duties in all material respects, adhering to confidentiality and non-compete obligations, and executing a release in favor of the Company, which typically includes a six-month non-solicitation obligation.